Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
2 cycles induction chemotherapy
The First People's Hospital of Lianyungang
Locally Advanced Nasopharyngeal Carcinoma
1 trial -
Induction Chemotherapy
The First People's Hospital of Lianyungang
Locally Advanced Nasopharyngeal Carcinoma
1 trial -
Ixazomib, thalidomide, & dexamethasone (ITD) re-induction
Takeda
Multiple Myeloma
1 trial -
JPB898 (Induction and Maintenance)
Sandoz Pty Ltd
Melanoma
1 trial -
PF-06651600 Induction Dose
Pfizer
Alopecia Areata
1 trial -
R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm
Takeda
Multiple Myeloma
1 trial -
SODIUM CHLORIDE, Truxima 500 mg concentrate for solution for infusion
Pari Pharma GmbH
Patient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%) following RTX induction treatment
1 trial -
Vidaza 25 mg/ml powder for suspension for injection, Gilteritinib
Astellas Pharma GmbH
Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
1 trial -
gemcitabine and cisplatin (Induction chemotherapy)
Sun Yat-sen University
Nasopharyngeal Carcinoma
1 trial -
gemcitabine and cisplatin (Induction chemotherapy)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
misoprostol
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Labor Induction
1 trial -
2 cycles of combined drug induction therapy: every 3 weeks for 2 cycles; After ,synchronous radiotherapy and chemotherapy combined immunotherapy
The First People's Hospital of Lianyungang
Cervical Cancer Stage IVA
1 trial -
A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
Amgen
Ulcerative Colitis (UC)
1 trial -
A clinical study to evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination with Daratumumab SC (Tal-D) and Teclistamab SC in Combination with Daratumumab SC (Tec-D) Following Induction with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants with Standard-risk Newly Diagnosed Multiple
Janssen-Cilag International N.V.
Multiple Myeloma
1 trial -
Induction Therapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli,SBLPN
1 trial -
Induction of neo-antigen specific T cells by specialized cross-presenting dendritic cells in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy, the NEODOC study
Disc Medicine
Ovarian cancer
1 trial -
Induction therapy of GP(Pomalidomide+Obinutuzumab)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Indolent Lymphoma
1 trial -
Loc-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction treatment for patients aged 18 to 60 (up to 65 for phase II) with a newly diagnosed Primary Central Nervous System Lymphoma
The George Institute
Primary Central Nervous System Lymphoma (PCNSL)
1 trial -
ORKA-001 Induction Dose
Oruka Therapeutics
Plaque Psoriasis
1 trial -
TPC induction chemotherapy
Sun Yat-sen University
Nasopharyngeal Carcinoma
1 trial -
Zaunbrutinib, Bendamustine and Rituximab for induction therapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Waldenström Macroglobulinemia (WM)
1 trial -
induction chemotherapy and immunotherapy
The First People's Hospital of Lianyungang
ESCC
1 trial -
Evaluation of vamorolone CYP3A4 induction on midazolam (a sensitive CYP3A4 substrate) pharmacokinetics
Lacuna Pharma Pty Ltd
Phase I study in healthy male volunteers. Intended indication: Duchenne muscular dystrophy and Becker muscular dystrophy
1 trial -
BUP microdose induction
BRIGHT MINDS BIOSCIENCES INC.
Substance Use Disorders
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources